Volume 18, Number 2—February 2012
Dispatch
Multiorgan Dysfunction Caused by Travel-associated African Trypanosomiasis
Table 2
Reports to ProMED-mail of Trypanosoma brucei rhodesiense infections associated with travel to or bordering Zambia, 2010*
Month of report | ProMED-mail archive no. | Nationality of patient | Travel activity | Area visited |
---|---|---|---|---|
September | 20100915.3338 | Zambian | Visiting game ranch | South Luangwa Valley, Zambia |
20100915.3338 | American | Hunting safari | South Luangwa Valley, Zambia | |
October† | 20101022.3833 | British | Camping safari | South Luangwa National Park, Lower Zambez National Park, Kafu National Park, Zambia |
20101022.3833 | British | Visiting national park | Mana Pool National Park, Zimbabwe (bordering Zambia) | |
November | 20101111.4093 | South African national of Scandinavian origin | Hiking | Luangwa River area, Zambia |
*Reports in (6). Since the start of 2005, 11 other cases of T. b. rhodesiense infection in travelers have been reported in ProMED-mail; those cases were acquired in Uganda (1), Tanzania (3), and Malawi (7).
†Case presented in this report.
References
- Welburn SC, Picozzi K, Fèvre EM, Coleman PG, Odiit M, Carrington M, Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet. 2001;358:2017–9. DOIPubMedGoogle Scholar
- Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148–59. DOIPubMedGoogle Scholar
- Abramowicz M. Drugs for parasitic infections. In: Abramowicz M, editor. The medical letter on drugs and therapeutics. New Rochelle (NY): The Medical Letter, Inc; 2000. p. 1–12.
- Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol. 2008;64:116–26. DOIPubMedGoogle Scholar
- Gautret P, Clerinx J, Caumes E, Simon F, Jensenius M, Loutan L, Imported human African trypanosomiasis in Europe, 2005–2009. Euro Surveill. 2009;14:pii:19327. PubMedGoogle Scholar
- ProMED-mail. Archive nos. 20100915.3338, 20101022.3833, and 20101111.4093 [cited 2011 Sep 22]. http://www.promedmail.org
- Sinha A, Grace C, Alston WK, Westenfeld F, Maguire JH. African trypanosomiasis in two travelers from the United States. Clin Infect Dis. 1999;29:840–4. DOIPubMedGoogle Scholar
- Reincke M, Arlt W, Heppner C, Petzke F, Chrousos GP, Allolio B. Neuroendocrine dysfunction in African trypanosomiasis. Ann N Y Acad Sci. 1998;840:809–21. DOIPubMedGoogle Scholar
- Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology. 2010;137:1987–94. DOIPubMedGoogle Scholar
- Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol. 2009;211:16–22. DOIPubMedGoogle Scholar
- World Health Organization. Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. WHO Technical Report Series. 1998;881:I–VI, 1–114.
- Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Apolipoprotein L–I is the trypanosome lytic factor of human serum. Nature. 2003;422:83–7. DOIPubMedGoogle Scholar
- Pays E, Vanhollebeke B. Human innate immunity against African trypanosomes. Curr Opin Immunol. 2009;21:493–8. DOIPubMedGoogle Scholar
- Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, Human Trypanosoma evansi infection linked to a lack of apolipoprotein L–I. N Engl J Med. 2006;355:2752–6. DOIPubMedGoogle Scholar
1Current affiliation: Worthing Hospital, Worthing, UK.